

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Hiroyuki SAITO et al.
Title: PREVENTION AND TREATMENT
OF BLOOD COAGULATION-
RELATED DISEASES
Appl. No.: Unassigned
Filing Date: 03/29/2002
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Box PCT
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

Atty. Dkt. No. 053466-0325

RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding International application. Copies of the documents are not being provided since copies should have been provided directly by WIPO under an exchange program between the PTO, the EPO and the JPO.

A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner. English-language translations of the foreign-language documents have not been provided. The absence of a translation or an English-language counterpart document does not relieve the PTO from its duty to consider any submitted document (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date March 29, 2002By FOLEY & LARDNER
Customer Number: 22428

22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5571

Facsimile: (202) 672-5399

Harold C. Wegner
Attorney for Applicants
Registration No. 25,258

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. **1613 Rev'd PCT/PTO 2.0 MAR 2002**

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 29, 2002 (use as many sheets as necessary)		Complete if Known <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <td style="width:50%;">Application Number</td> <td>Unassigned</td> </tr> <tr> <td>Filing Date</td> <td>03/29/2002</td> </tr> <tr> <td>First Named Inventor</td> <td>Hiroyuki SAITO</td> </tr> <tr> <td>Group Art Unit</td> <td>Unassigned</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>053466-0325</td> </tr> </table>		Application Number	Unassigned	Filing Date	03/29/2002	First Named Inventor	Hiroyuki SAITO	Group Art Unit	Unassigned	Examiner Name	Unassigned	Attorney Docket Number	053466-0325
Application Number	Unassigned														
Filing Date	03/29/2002														
First Named Inventor	Hiroyuki SAITO														
Group Art Unit	Unassigned														
Examiner Name	Unassigned														
Attorney Docket Number	053466-0325														
Sheet	1	of	1												

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	5,346,991		ROY et al.	09/13/1994	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A2	IL	85411		GENENTECH, INC.	07/31/1998		
	A3	WO	88/09817		NEMERSON et al.	12/15/1988		
	A4	WO	88/07543		EDGINGTON et al.	10/06/1988		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A5	RANDOLPH, G. et al. "Role of Tissue Factor in Adhesion of Mononuclear Phagocytes to and Trafficking Through Endothelium In Vitro," <i>Blood</i> (December 1, 1998), Vol. 92, No. 11, pp. 4167-4177.		
	A6	GIESEN, P. et al. "Blood-borne tissue factor: Another view of thrombosis," <i>Proc. Natl. Acad. Sci.</i> (March 1999), Vol. 96, pp. 2311-2315.		
	A7	NAKAYAMA, T. et al., (1999) Vol. 39, No. 4, 298-302.		
	A8	DRAKE, T. et al. "Functional Tissue Factor Is Entirely Cell Surface Expressed on Lipopolysaccharide-stimulated Human Blood Monocytes and a Constitutively Tissue Factor-producing Neoplastic Cell Line," <i>The Journal of Cell Biology</i> (July 1989), Vol. 109, pp. 389-395, The Rockefeller University Press.		
	A9	RAN, S. et al. "Infarction of Solid Hodgkin's Tumors in Mice by Antibody-directed Targeting of Tissue Factor to Tumor Vasculature," <i>Cancer Research</i> (October 15, 1998), pp. 4646-4653.		
	A10	BELLAMY, W. et al. "Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype," <i>Cancer Chemother Pharmacol</i> (1996), Vol. 37, pp. 305-316.		
	A11	HUANG, X. et al. "Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature," <i>Science</i> (24 January 1997), Vol. 275, pp. 547-550.		
	A12	MORRISSEY, J. "Molecular Cloning of the cDNA for Tissue Factor, the Cellular Receptor for the Initiation of the Coagulation Protease Cascade," <i>Cell</i> (July 3, 1987), Vol. 50, pp. 129-135, Cell Press.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 606. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Civil Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.